STOCK TITAN

Humana Financials

HUM
Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Humana (HUM) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 19 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Profitability Growth Leverage Liquidity Cash Flow Returns 42 / 100
Financial Profile 42/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability
27

Humana has an operating margin of 2.1%, meaning the company retains $2 of operating profit per $100 of revenue. This below-average margin results in a low score of 27/100, suggesting thin profitability after operating expenses. This is down from 2.2% the prior year.

Growth
50

Humana's revenue grew 10.1% year-over-year to $129.7B, a solid pace of expansion. This earns a growth score of 50/100.

Leverage
88

Humana carries a low D/E ratio of 0.70, meaning only $0.70 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 88/100, indicating a strong balance sheet with room for future borrowing.

Liquidity
36

Humana's current ratio of 2.00 indicates adequate short-term liquidity, earning a score of 36/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow
26

Humana's free cash flow margin of 0.3% results in a low score of 26/100. Capital expenditures of $546.0M absorb a large share of operating cash flow.

Returns
26

Humana generates a 6.7% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 26/100. This is down from 7.4% the prior year.

Altman Z-Score Safe
4.47

Humana scores 4.47, well above the 2.99 safe threshold. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Piotroski F-Score Neutral
5/9

Humana passes 5 of 9 financial strength tests. 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Mixed
0.78x

For every $1 of reported earnings, Humana generates $0.78 in operating cash flow ($921.0M OCF vs $1.2B net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.

Interest Coverage Adequate
4.3x

Humana earns $4.3 in operating income for every $1 of interest expense ($2.7B vs $631.0M). This adequate coverage means the company can meet its interest obligations, but has limited cushion if earnings fall.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$129.7B
YoY+10.1%
5Y CAGR+10.9%
10Y CAGR+9.1%

Humana generated $129.7B in revenue in fiscal year 2025. This represents an increase of 10.1% from the prior year.

EBITDA
$3.4B
YoY+0.0%
5Y CAGR-9.5%
10Y CAGR+2.3%

Humana's EBITDA was $3.4B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 0.0% from the prior year.

Net Income
$1.2B
YoY-1.6%
5Y CAGR-18.8%
10Y CAGR-0.7%

Humana reported $1.2B in net income in fiscal year 2025. This represents a decrease of 1.6% from the prior year.

EPS (Diluted)
$9.84
YoY-1.4%
5Y CAGR-17.2%
10Y CAGR+1.5%

Humana earned $9.84 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 1.4% from the prior year.

Cash & Balance Sheet

Free Cash Flow
$375.0M
YoY-84.3%
5Y CAGR-39.6%
10Y CAGR+0.8%

Humana generated $375.0M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 84.3% from the prior year.

Cash & Debt
$4.2B
YoY+89.1%
5Y CAGR-2.1%
10Y CAGR+5.0%

Humana held $4.2B in cash against $12.4B in long-term debt as of fiscal year 2025.

Dividends Per Share
$3.54
YoY+0.0%
5Y CAGR+7.8%
10Y CAGR+11.9%

Humana paid $3.54 per share in dividends in fiscal year 2025. This represents an increase of 0.0% from the prior year.

Shares Outstanding
121M
YoY-0.0%
5Y CAGR-1.3%
10Y CAGR-2.0%

Humana had 121M shares outstanding in fiscal year 2025. This represents a decrease of 0.0% from the prior year.

Margins & Returns

Gross Margin
N/A
Operating Margin
2.1%
YoY-0.1pp
5Y CAGR-4.4pp
10Y CAGR-2.2pp

Humana's operating margin was 2.1% in fiscal year 2025, reflecting core business profitability. This is down 0.1 percentage points from the prior year.

Net Margin
0.9%
YoY-0.1pp
5Y CAGR-3.4pp
10Y CAGR-1.4pp

Humana's net profit margin was 0.9% in fiscal year 2025, showing the share of revenue converted to profit. This is down 0.1 percentage points from the prior year.

Return on Equity
6.7%
YoY-0.6pp
5Y CAGR-17.8pp
10Y CAGR-5.6pp

Humana's ROE was 6.7% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 0.6 percentage points from the prior year.

Capital Allocation

R&D Spending
N/A
Share Buybacks
$151.0M
YoY-81.5%
5Y CAGR-39.2%
10Y CAGR-8.9%

Humana spent $151.0M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 81.5% from the prior year.

Capital Expenditures
$546.0M
YoY-5.0%
5Y CAGR-10.7%
10Y CAGR+0.4%

Humana invested $546.0M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 5.0% from the prior year.

HUM Income Statement

Metric Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24 Q2'24 Q1'24
Revenue $32.5B-0.4% $32.6B+0.8% $32.4B+0.9% $32.1B+9.9% $29.2B-0.6% $29.4B-0.5% $29.5B-0.2% $29.6B
Cost of Revenue N/A N/A N/A N/A N/A N/A N/A N/A
Gross Profit N/A N/A N/A N/A N/A N/A N/A N/A
R&D Expenses N/A N/A N/A N/A N/A N/A N/A N/A
SG&A Expenses $4.4B+8.6% $4.1B+15.2% $3.5B+4.9% $3.4B-18.9% $4.2B+24.8% $3.3B+6.1% $3.1B+3.5% $3.0B
Operating Income -$808.0M-302.0% $400.0M-63.6% $1.1B-45.5% $2.0B+470.9% -$543.0M-174.6% $728.0M-36.2% $1.1B-7.7% $1.2B
Interest Expense $146.0M-13.1% $168.0M+7.0% $157.0M-1.9% $160.0M-2.4% $164.0M-3.0% $169.0M+0.6% $168.0M+5.7% $159.0M
Income Tax -$249.0M-189.5% -$86.0M-148.0% $179.0M-55.9% $406.0M+288.0% -$216.0M-239.4% $155.0M-30.5% $223.0M-11.2% $251.0M
Net Income -$796.0M-508.2% $195.0M-64.2% $545.0M-56.2% $1.2B+279.5% -$693.0M-244.4% $480.0M-29.3% $679.0M-8.4% $741.0M
EPS (Diluted) N/A $1.62-64.1% $4.51-56.2% $10.30 N/A $3.98-29.2% $5.62-8.0% $6.11

HUM Balance Sheet

Metric Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24 Q2'24 Q1'24
Total Assets $48.9B-1.6% $49.7B-1.3% $50.4B-1.1% $50.9B+9.6% $46.5B-7.1% $50.0B-0.2% $50.1B0.0% $50.1B
Current Assets $32.7B-0.1% $32.8B-2.6% $33.6B-2.3% $34.4B+15.5% $29.8B-9.4% $32.9B+0.2% $32.9B+0.2% $32.8B
Cash & Equivalents $4.2B-22.0% $5.4B+33.4% $4.0B-4.9% $4.3B+91.4% $2.2B-56.6% $5.1B-7.0% $5.5B-6.9% $5.9B
Inventory N/A N/A N/A N/A N/A N/A N/A N/A
Accounts Receivable N/A N/A N/A N/A N/A N/A N/A N/A
Goodwill $9.7B+0.7% $9.6B-0.1% $9.6B0.0% $9.6B0.0% $9.6B+0.4% $9.6B+0.2% $9.6B0.0% $9.6B
Total Liabilities $31.2B+0.1% $31.1B-2.9% $32.1B-3.2% $33.1B+10.2% $30.0B-7.3% $32.4B-2.9% $33.4B-1.6% $33.9B
Current Liabilities $16.3B+1.0% $16.2B-6.0% $17.2B-4.6% $18.0B+6.5% $16.9B-9.5% $18.7B-5.4% $19.8B+0.5% $19.7B
Long-Term Debt $12.4B-1.9% $12.6B+0.2% $12.6B-1.1% $12.7B+14.2% $11.1B-6.2% $11.9B+1.2% $11.7B-5.2% $12.4B
Total Equity $17.7B-4.7% $18.5B+1.6% $18.2B+2.7% $17.8B+8.4% $16.4B-6.8% $17.6B+5.4% $16.7B+3.4% $16.1B
Retained Earnings $29.1B-3.0% $30.0B+0.3% $29.9B+1.5% $29.5B+4.0% $28.3B-2.8% $29.1B+1.3% $28.7B+2.0% $28.2B

HUM Cash Flow Statement

Metric Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24 Q2'24 Q1'24
Operating Cash Flow -$1.7B-270.1% $971.0M-23.6% $1.3B+284.0% $331.0M+162.7% -$528.0M-128.4% $1.9B+53.2% $1.2B+186.8% $423.0M
Capital Expenditures $202.0M+49.6% $135.0M+18.4% $114.0M+20.0% $95.0M-38.3% $154.0M+18.5% $130.0M+14.0% $114.0M-35.6% $177.0M
Free Cash Flow -$1.9B-321.8% $836.0M-27.7% $1.2B+390.3% $236.0M+134.6% -$682.0M-139.5% $1.7B+57.2% $1.1B+346.7% $246.0M
Investing Cash Flow $632.0M-35.5% $980.0M+182.4% $347.0M+10.5% $314.0M+598.4% -$63.0M+95.7% -$1.5B-47.0% -$1.0B-142.0% -$414.0M
Financing Cash Flow -$168.0M+72.1% -$603.0M+67.0% -$1.8B-232.1% $1.4B+160.1% -$2.3B-199.2% -$770.0M-24.2% -$620.0M-151.4% $1.2B
Dividends Paid $109.0M+1.9% $107.0M+0.9% $106.0M-1.9% $108.0M0.0% $108.0M+0.9% $107.0M0.0% $107.0M-1.8% $109.0M
Share Buybacks $42.0M $0-100.0% $100.0M+1011.1% $9.0M-81.6% $49.0M+2350.0% $2.0M-95.9% $49.0M-93.2% $717.0M

HUM Financial Ratios

Metric Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24 Q2'24 Q1'24
Gross Margin N/A N/A N/A N/A N/A N/A N/A N/A
Operating Margin -2.5%-3.7pp 1.2%-2.2pp 3.4%-2.9pp 6.3%+8.1pp -1.9%-4.3pp 2.5%-1.4pp 3.9%-0.3pp 4.2%
Net Margin -2.5%-3.0pp 0.6%-1.1pp 1.7%-2.2pp 3.9%+6.2pp -2.4%-4.0pp 1.6%-0.7pp 2.3%-0.2pp 2.5%
Return on Equity -4.5%-5.6pp 1.1%-1.9pp 3.0%-4.0pp 7.0%+11.2pp -4.2%-7.0pp 2.7%-1.3pp 4.1%-0.5pp 4.6%
Return on Assets -1.6%-2.0pp 0.4%-0.7pp 1.1%-1.4pp 2.4%+3.9pp -1.5%-2.5pp 1.0%-0.4pp 1.4%-0.1pp 1.5%
Current Ratio 2.00-0.0 2.02+0.1 1.95+0.0 1.91+0.1 1.760.0 1.76+0.1 1.660.0 1.67
Debt-to-Equity 0.70+0.0 0.680.0 0.69-0.0 0.72+0.0 0.680.0 0.68-0.0 0.70-0.1 0.77
FCF Margin -5.7%-8.3pp 2.6%-1.0pp 3.6%+2.8pp 0.7%+3.1pp -2.3%-8.2pp 5.9%+2.2pp 3.7%+2.9pp 0.8%

Similar Companies

Frequently Asked Questions

Humana (HUM) reported $129.7B in total revenue for fiscal year 2025. This represents a 10.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Humana (HUM) revenue grew by 10.1% year-over-year, from $117.8B to $129.7B in fiscal year 2025.

Yes, Humana (HUM) reported a net income of $1.2B in fiscal year 2025, with a net profit margin of 0.9%.

Humana (HUM) reported diluted earnings per share of $9.84 for fiscal year 2025. This represents a -1.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Humana (HUM) had EBITDA of $3.4B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

As of fiscal year 2025, Humana (HUM) had $4.2B in cash and equivalents against $12.4B in long-term debt.

Humana (HUM) had an operating margin of 2.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

Humana (HUM) had a net profit margin of 0.9% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Yes, Humana (HUM) paid $3.54 per share in dividends during fiscal year 2025.

Humana (HUM) has a return on equity of 6.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Humana (HUM) generated $375.0M in free cash flow during fiscal year 2025. This represents a -84.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Humana (HUM) generated $921.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

Humana (HUM) had $48.9B in total assets as of fiscal year 2025, including both current and long-term assets.

Humana (HUM) invested $546.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Yes, Humana (HUM) spent $151.0M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

Humana (HUM) had 121M shares outstanding as of fiscal year 2025.

Humana (HUM) had a current ratio of 2.00 as of fiscal year 2025, which is generally considered healthy.

Humana (HUM) had a debt-to-equity ratio of 0.70 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

Humana (HUM) had a return on assets of 2.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Humana (HUM) has an Altman Z-Score of 4.47, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Humana (HUM) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Humana (HUM) has an earnings quality ratio of 0.78x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Humana (HUM) has an interest coverage ratio of 4.3x, meaning it can adequately cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

Humana (HUM) scores 42 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.

Back to top